Sladjana Filipovic

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations

Breast Oncology, Medicine, Primary Analysis +7

Stressful life events and breast cancer risk: a hospital-based case-control study.

Biljana Kocić, Sladjana Filipovic, Svetislav Vrbić et al. · PubMed · 2015 · 13 citations

Young age and pathological features predict breast cancer outcome - report from a dual Institution experience in Serbia.

Ana Cvetanović, Lazar Popović, Sladjana Filipovic et al. · PubMed · 2016 · 12 citations